Linked Off-Site Content Attributed to the Vendor
Updated September 5, 2026
FDA warning letter 721600 to Mile High Compounds LLC documents a distinct evidence category: content hosted on a linked third-party community platform, quoted as the vendor's own labeling. The letter reviews the company's website "which links to your community forum" and cites usage and dosing material found there. Letter date: March 31, 2026.
The letter behind the category
Mile High Compounds LLC of Clifton, Colorado received warning letter 721600, dated March 31, 2026 — one of seven letters to research-peptide sellers signed that day and made public on April 7, 2026. The review window recorded for this company ran January through March 2026, so the observation preceded the letter by months. This page records one evidentiary method from that letter; the letter as a whole is documented at the Mile High Compounds letter record, and the seven-letter release at the April 2026 batch record.
What the letter reviewed
The letter's scope statement is the record's key sentence. FDA describes reviewing the company's website, "which links to your community forum" — a community hosted on a third-party platform (skool.com), not on the company's own domain. Material found on that forum was then quoted in the letter as evidence of the intended use of the company's products, under the same intended-use regulation the whole batch rests on, 21 CFR 201.128.
The attribution logic is visible in the sequence: the vendor's site carried the link; the linked destination carried the content; the letter cites that content as the vendor's. Hosting arrangements and platform ownership did not enter into it — what mattered, per the letter, was that the vendor's own website pointed its visitors there.
The material, described at category level
The forum content the letter quotes consisted of usage and dosing material — cheat-sheet-style pages setting out how the compounds in question would be used. This index does not reproduce any of it: no figures, no compound-by-compound entries, no quoted phrasing. Per this site's register rules, agency findings are described by category and the letter itself is cited as the primary document.
A neutral product page did not offset the link
The record's second lesson sits alongside the first. The product listings on the company's own domain are not what the letter leans on; the quoted evidence came from the linked forum. A product page free of intended-use language did not offset that material — the evidentiary unit was the website plus what it linked to, read together. In the letter's framing, the link made the off-site material part of the vendor's presentation of its products.
Where this sits among the documented methods
The December 10, 2024 letters had already established that review extends past product pages: social properties, video content, and on-domain blog posts were each quoted in that batch. The March 31, 2026 batch extended the surface again — two letters open on marketplace storefronts, and the Mile High letter reaches content the vendor neither wrote on its own domain nor hosted anywhere it controlled. Within this index's record, letter 721600 is the first instance of linked off-site community content attributed to a vendor as labeling evidence.
The category has since taken one further step. In the batch of five letters FDA signed on August 24, 2026, one letter cites a page on PubChem — a chemical database run by the National Center for Biotechnology Information, part of the U.S. National Library of Medicine — and gives the same stated ground, that the page was hyperlinked from
the firm's product page. The difference from letter 721600 is the kind of destination: a community forum is a place a seller cultivates, and a government scientific database is not. The practice remains uncommon. Across the five letters in that batch, 31 of the 32 webpages FDA quoted sit on the seller's own domain, and four of the five letters cite no off-site source at all. The batch record is at FDA warning letters of August 24, 2026.
Record summary
| Entity | Mile High Compounds LLC, Clifton, Colorado |
|---|---|
| Letter number | 721600 |
| Letter date / posting date | March 31, 2026 / April 7, 2026 |
| Review window | January–March 2026 |
| Evidence category recorded here | Usage and dosing material on a linked third-party community forum, quoted as the vendor's labeling |
| Regulation cited | 21 CFR 201.128 (intended use) |
| Response demanded | Within 15 working days, by email to FDAADVISORY@fda.hhs.gov |
| Escalation wording | "seizure and injunction" |
| Outcome | Unknown — no close-out or follow-on action found as of August 25, 2026 |
What the record does not contain
No response from Mile High Compounds appears in the public record this index has verified, and no close-out letter or follow-on action had been located as of the dateline above. The outcome is unknown and is recorded as unknown. The company's entry sits with all named recipients in the vendor closure and enforcement index.
Sources
- FDA Warning Letter, Mile High Compounds LLC, 721600-03312026. fda.gov
- FDA Warning Letters database. fda.gov
- Policy Canary — April 2026 FDA research-peptide warning-letter batch. policycanary.io
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.